valsartan has been researched along with Graft-Versus-Host Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatou, S; Imada, T; Ishida, S; Kawakami, Y; Kawakita, T; Miyashita, H; Mori, T; Nakamura, S; Ogawa, Y; Okamoto, S; Ozawa, Y; Satofuka, S; Shimmura, S; Tsubota, K; Yaguchi, S; Yaguchi, T; Yoshida, S | 1 |
1 other study(ies) available for valsartan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression; Graft vs Host Disease; Histocompatibility Testing; Humans; Imidazoles; Lacrimal Apparatus; Liver; Lung; Male; Mice; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2013 |